These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16284682)

  • 21. Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
    Umbricht A; Huestis MA; Cone EJ; Preston KL
    J Clin Psychopharmacol; 2004 Oct; 24(5):479-87. PubMed ID: 15349002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soft tissue infections of the upper extremities with special consideration of abscesses in parenteral drug abusers. A prospective study.
    Simmen HP; Giovanoli P; Battaglia H; Wüst J; Meyer VE
    J Hand Surg Br; 1995 Dec; 20(6):797-800. PubMed ID: 8770744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disaccharides in urine samples as markers of intravenous abuse of methadone and buprenorphine.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2013; 37(9):652-8. PubMed ID: 24099717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-losing enteropathy post-valvular surgery with severe tricuspid regurgitation in Subutex-related endocarditis.
    Lee LC; Wong R; Raju GC; Khor C; Yip J
    Singapore Med J; 2009 Apr; 50(4):e124-6. PubMed ID: 19421664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protean manifestations of intravenous drug use.
    Warner RM; Srinivasan JR
    Surgeon; 2004 Jun; 2(3):137-40. PubMed ID: 15570814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications arising from intravenous buprenorphine abuse.
    Seet RC; Oh VM; Lim EC
    QJM; 2007 May; 100(5):312-3. PubMed ID: 17456611
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Withdrawal syndrome in 2 drug addicts after intravenous injection of buprenorphine?].
    Gourarier L; Lowenstein W; Gisselbrecht M; Chauveau JM; Haas C; Durand H
    Presse Med; 1996 Sep; 25(27):1239-40. PubMed ID: 8949735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High buprenorphine-related mortality is persistent in Finland.
    Kriikku P; Häkkinen M; Ojanperä I
    Forensic Sci Int; 2018 Oct; 291():76-82. PubMed ID: 30170272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners.
    Tompkins CN; Wright NM; Waterman MG; Sheard L
    Int J Prison Health; 2009; 5(2):71-87. PubMed ID: 25759139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Abuse of buprenorphine becomes a problem of the Czech Republic].
    Nespor K; Csémy L
    Cas Lek Cesk; 2006; 145(1):59-60. PubMed ID: 16468244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
    Simojoki K; Lillsunde P; Lintzeris N; Alho H
    Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.
    Wilson RM; Elmaraghi S; Rinker BD
    Hand (N Y); 2017 Sep; 12(5):507-511. PubMed ID: 28832211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Infected brachial artery pseudoaneurysm--infrequent complication secondary to parenteral drug abuse].
    Biros E; Maresch M; Rathous I; Sváb J
    Rozhl Chir; 2007 Jun; 86(6):309-11. PubMed ID: 17695041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetanus in an injecting buprenorphine abuser.
    Teo FS; Hsu LY; Lam KN; Johan A
    Ann Acad Med Singap; 2007 Dec; 36(12):1021-3. PubMed ID: 18185883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why do the clients of Georgian needle exchange programmes inject buprenorphine?
    Otiashvili D; Zabransky T; Kirtadze I; Piralishvili G; Chavchanidze M; Miovsky M
    Eur Addict Res; 2010; 16(1):1-8. PubMed ID: 19887803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaphylaxis after the injection of buprenorphine.
    Boggs CL; Ripple MG; Ali Z; Brassell M; Levine B; Jufer-Phipps R; Doyon S; Fowler DR
    J Forensic Sci; 2013 Sep; 58(5):1381-1383. PubMed ID: 23550514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.